Speaker
Description
Background: Clinical Trial Data Sharing (CTDS) for secondary use could improve research transparency and reproducibility. Despite journal and regulatory mandates, actual sharing of data remains rare. While 68.6% of trials intend to share data, under 1% make de-identified datasets public upon publication. CTDS is further hindered by privacy concerns, unharmonized data, and inadequate incentives. This study maps stakeholder perspectives to characterize existing governing frameworks and recommend equitable data sharing strategies.
Methods: Following JBI methodology and PRISMA-ScR guidelines, we systematically searched PubMed, EMBASE, and Web of Science (April 2025), alongside citation tracking (through February 2026). We included English-language articles (2019–2025) addressing CTDS stakeholder perspectives. Screening utilized a Population-Concept-Context framework, followed by inductive content analysis.
Results: Of 4,615 records identified, 43 met inclusion criteria, predominantly from Europe and the Americas (68%). Patients and researchers were the most studied stakeholders, while funder perspectives were not identified in our search. Seven cross-cutting themes emerged: privacy, altruism, scientific progress, consent, oversight, trust, and infrastructure. Key barriers included data protection concerns, administrative burden, and fear of scooping, whereas altruism and mandates were primary motivators. Regulatory literacy was universally lacking. Broad consent is operationally preferred but ethically contested.
Discussion: Operationalizing CTDS requires systemic shifts through infrastructure, policy, and cultural reform. We propose eight recommendations: implement data literacy training, modernize broad consent, reform academic incentives, institute independent multi-stakeholder governance, enable community involvement, expand research on underrepresented stakeholders, invest in shared infrastructures, and establish transparent benefit-sharing mechanisms.